A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Inclusion Criteria:
Exclusion Criteria:
Metairie, Louisiana 70006, United States
New York, New York 10032, United States
Haine-St-Paul, 7100, Belgium
Joinville, 89201-260, Brazil
Rio de Janeiro, 22775-001, Brazil
São José do Rio Preto, 15090-000, Brazil
Montreal, Quebec H1T 2M4, Canada
Ostrava - Poruba, 708 52, Czechia
Athens Attica, 115 28, Greece
Gunma, 377-0280, Japan
Iruma-gun, 350-0495, Japan
Staffordshire, ST4 6QG, United Kingdom